NEUP Neuphoria Company Profit

NEUP (Neuphoria Therapeutics Inc.) - company brandmark

Neuphoria Therapeutics Inc. minimizes risks by developing a range of independent CNS drugs. The company's profit dynamics visualize this process, with the value holding at -0.01. The brand's scientific authority is based on the creation of a safe therapy for anxiety disorders. However, the absence of commercial products makes the company's financial condition dependent on external funding and grants.

Net Income: Neuphoria Therapeutics (NEUP) for 12/25/2024 - 11/01/2026

Financial and market metric breakdowns for bionomics.com.au (NEUP)

- stock value and consensus price forecast:
Market Price Neuphoria Therapeutics|NEUP - Price Target Chart
- market capitalization data:
Market Capitalization Neuphoria Therapeutics Inc.|NEUP - Enterprise Value
- book capitalization information:
Net Asset Value per Share Neuphoria Therapeutics|NEUP - Company Net Assets|Market Capitalization to Book Value Ratio bionomics.com.au|NEUP - Aggregate Company Assets
- debt burden and liquidity indicators:
Aggregate Debt to Equity Neuphoria Therapeutics Inc.|NEUP - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Neuphoria Therapeutics|NEUP - Company Debts|Debts to Book Value Neuphoria Therapeutics Inc.|NEUP - Company Long-Term Debt|Company Short-Term Loans and Borrowings Neuphoria Therapeutics|Interim Coverage Ratio bionomics.com.au
- company profitability and valuation multiples indicators:
NEUP - Net Profit
Basic company analysis:NEUP Neuphoria
Product sample of Neuphoria Therapeutics, Inc.

This indicator calculates daily net income, providing a real-time assessment of the difference between current inflows and expenses without waiting for quarterly reports. For the biotech startup Neuphoria Therapeutics Inc. (NEUP), which invests in the modulation of brain ion channels, such granularity is critical for evaluating burn rates, making the company's profit dynamics a key tool for monitoring financial stability during the development of innovative drugs.

Main competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|Company Profit RGC (regencellbioscience.com)|Net Profit AXSM|ACAD - Company Net Income|Xenon Pharmaceuticals Inc - Net Income|Net Profit Viking Therapeutics Corp VKTX|SUPN - Company Net Income|Profit After Tax CPRX|DNLI: Net Profit|Harmony Biosciences Inc - Final Profit|Company Net Income Biohaven Pharmaceutical|Company Net Income Amylyx Corp AMLX|Company Net Income Trevi Therapeutics (TRVI)|PRAX (praxismedicines.com) - Final Profit|Net Profit AVXL (Anavex Life Sciences Corp.)|Net Financial Result CeriBell Inc (CBLL)|Prothena Biosciences - Net Profit|ALEC - Net Profit|ANNX (Annexon, Inc.) - Net Income|Omeros - Final Profit|Net Income NGNE|ACIU (AC Immune S.A.) - Profit After Payment of Taxes|Net Profit VYGR|NMRA (Neumora Corp) - Final Profit|Net Profit SCLX (Scilex Holding Company)|tevogen.com (TVGN) - Company Net Income|ACOG - Company Net Income|Final Profit CGTX (cogrx.com)|IKT: Net Profit|Cassava Pharma (SAVA) - Net Profit|Company Net Income Assertio Holdings|Coya - Profit After Tax|Net Profit VTGN|OVID - Company Net Income|Acumen Pharma - Net Income|Net Profit CervoMed Corporation CRVO|ATHE: Net Income|Clene Inc. - Profit After Payment of Taxes|PEPG: Net Profit|JUNS - Net Financial Result|RLMD (Relmada) - Net Profit|Net Income Annovis Bio Corporation (ANVS)|Company Net Income Grace Therapeutics, Inc. (GRCE)|Net Financial Result fireflyneuro.com|Klotho Neurosciences - Net Income|Final Profit NRSN|Reviva Pharmaceuticals Holdings - Net Profit|Net Financial Result MetaVia Inc MTVA|NeurAxis, Inc. (NRXS) - Company Net Income|Company Profit HSDT|PASG (Passage Bio Inc.) - Net Profit|Net Income Minerva Neurosciences Inc (NERV)|Net Income ATHA (Athira)|Net Financial Result Addex|Company Net Income Alzamend Neuro ALZN|CYCN: Company Profit|Protagenic - Net Profit|Company Net Income Pasithea Therapeutics|CRGT (cortigent.com) - Net Income|Avenue Therapeutics Inc (ATXI) - Net Profit|Company Net Income Brainstorm Cell|caratherapeutics.com - Profit After Tax|Company Net Income Chromocell Therapeutics Corp. (CHRO)|eliemtx.com - Company Profit|Net Profit ITCI (Intra-Cellular Therapies, Inc.)|Longboard (LBPH) - Company Net Income|MRNS: Net Income|NKGN - Net Profit|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Sage Therapeutics Inc. - Final Profit|Company Net Income Neurotrope|Company Net Income Trevena Inc TRVN|Company Net Income Vigil Neuroscience (VIGL)|Anew Medical Inc. - Company Profit|Net Profit CERE (Cerevel Therapeutics, Inc.)